

Trust specifics			
Deposit information			
Public offering price per unit ¹	\$10.00		
Minimum investment (\$250 for IRAs) ²	\$1,000.00		
Deposit date	02/08/24		
Termination date	02/12/26		
	ution dates 25th day of June, September, December and March		
Record dates 10t September, Decem	h day of June, ber and March		
Term of trust	24 months		
Symbol	IHCBDB		
Historical 12 month distributions ⁺	\$0.0575		
HCRX241 Sales charge and CUSIPs	5		
Brokerage			
Sales charge ³			
Deferred sales charge	2.25%		
Creation and development fee	0.50%		
Total sales charge	2.75%		
Last deferred sales charge payment date 11/10/24			
CUSIPs			
Cash	46150L-38-5		
Reinvest	46150L-39-3		
Historical 12 month distribution rate ⁺	0.57%		
Fee-based			
Sales charge ³			
Fee-based sales charge	0.50%		
CUSIPs			
Fee-based cash	46150L-40-1		
Fee-based reinvest	46150L-41-9		
Historical 12 month distribution rate ⁺ (fee-based)	0.59%		

Invesco Unit Trusts

Diversified Healthcare Portfolio 2024-1 A sector unit trust

Objective

The Portfolio seeks capital appreciation. The Portfolio seeks to achieve its objective by investing in a portfolio primarily consisting of stocks of companies diversified within the healthcare industry.


Portfolio composition (As of the busines	ss day before	deposit date)
Biotechnology		Health Car
AbbVie, Inc.	ABBV	Hoya Corpo
Amgen, Inc.	AMGN	Life Sciend
CSL, Ltd ADR	CSLLY	Mettler-Tole
Regeneron Pharmaceuticals, Inc.	REGN	Repligen Co
Vertex Pharmaceuticals, Inc.	VRTX	Thermo Fish
Health Care Distributors		Waters Corp
McKesson Corporation	MCK	West Pharm
Health Care Equipment		Managed H
Boston Scientific Corporation	BSX	Centene Cor
Edwards Lifesciences Corporation	EW	Elevance He
IDEXX Laboratories, Inc.	IDXX	Humana, Ind
Intuitive Surgical, Inc.	ISRG	UnitedHealt
Medtronic plc	MDT	Pharmace
Stryker Corporation	SYK	Astrazeneca
Health Care Facilities		Eli Lilly and
HCA Healthcare, Inc	HCA	Johnson &
Health Care Services		Merck & Cor
DaVita, Inc.	DVA	Novo Nordis
		Zastia lass

Health Care Supplies	
Hoya Corporation - ADR	HOCPY
Life Sciences Tools & Services	
Mettler-Toledo International, Inc.	MTD
Repligen Corporation	RGEN
Thermo Fisher Scientific, Inc.	ТМО
Waters Corporation	WAT
West Pharmaceutical Services, Inc.	WST
Managed Health Care	
Centene Corporation	CNC
Elevance Health, Inc.	ELV
Humana, Inc.	HUM
UnitedHealth Group, Inc.	UNH
Pharmaceuticals	
Astrazeneca plc - ADR	AZN
Eli Lilly and Company	LLY
Johnson & Johnson	JNJ
Merck & Company, Inc.	MRK
Novo Nordisk A/S - ADR CL B	NVO
Zoetis, Inc.	ZTS

The trust portfolio is provided for informational purposes only and should not be deemed as a recommendation to buy or sell the individual securities shown above.

Style breakdown

(As of the business day before deposit date)



Source: FactSet

Portfolio diversification

(As of the business day before deposit date)



See page 2 for the footnotes on trust specifics.

Not a Deposit Not FDIC Insured Not Guaranteed by the Bank May Lose Value Not Insured by any Federal Government Agency

Investors in fee-based accounts will not be assessed the deferred sales charge for eligible fee-based purchases and must purchase units with a Fee-based CUSIP.

⁺ The historical 12 month distributions per unit and each historical 12 month distribution rate of the securities included in the trust are for illustrative purposes only and are not indicative of the trust's actual distributions or distribution rate. The historical 12 month distributions per unit amount is based upon the weighted average of the actual distributions paid by the securities included in the trust over the 12 months preceding the trust's deposit date, and is reduced to account for the effects of fees and expenses which will be incurred when investing in a trust. Each historical 12 month distribution rate is calculated by dividing the historical 12 month distributions amount by the trust's initial \$10 public offering price per unit. There is no guarantee the issuers of the securities included in the trust will declare dividends or distributions in the future. The distributions paid by the trust, as well as the corresponding rates, may be higher or lower than the figures shown due to certain factors that may include, but are not limited to, a change in the dividends or distributions paid by issuers, actual expenses incurred, currency fluctuations, the sale of trust securities to pay any deferred sales charges, trust fees and expenses, variations in the trust's per unit price, or with the call, maturity or the sale of securities in the trust. Distributions made by certain securities in the trust may include non-ordinary income.

Portfolio selection

The companies selected for the Portfolio may share a variety of traits, among others, as of the time of selection, such as:

- Innovative products and services
- Operations within a market with high barriers to entry
- Ownership of highly valuable intangible assets such as patents and intellectual property
- FactSet Estimates* consensus analyst recommendation of "Hold" or better
- Attractive balance sheets
- Well-capitalized

*FactSet Estimates is a database that provides detail-level estimates and recommendations from many different contributing firms. FactSet Estimates translates the data into a uniform consensus average recommendation from the contributing firms.

About risk

There is no assurance the trust will achieve its investment objective. An investment in this unit investment trust is subject to market risk, which is the possibility that the market values of securities owned by the trust will decline and that the value of trust units may therefore be less than what you paid for them. This trust is unmanaged and its portfolio is not intended to change during the trust's life except in limited circumstances. Accordingly, you can lose money investing in this trust. The trust should be considered as part of a long-term investment strategy and you should consider your ability to pursue it by investing in successive trusts, if available. You will realize tax consequences associated with investing from one series to the next.

The financial condition of an issuer may worsen or its credit ratings may drop, resulting in a reduction in the value of your Units. This may occur at any point in time, including during the initial offering period.

You could experience dilution of your investment if the size of the Portfolio is increased as Units are sold. There is no assurance that your investment will maintain its proportionate share in the Portfolio's profits and losses.

A portfolio concentrated in a single market sector presents more risk than a portfolio broadly diversified over several market sectors. The Portfolio is concentrated in securities issued by companies in the health care industry. Companies involved in advanced medical devices and instruments, hospital management and biotechnology face risks such as extensive competition, product liability litigation, and evolving government regulation. Negative developments in the health care industry will affect the value of your investment more than would be the case in a more diversified investment.

Investing in companies operating in foreign countries involves certain risks not typically associated with investing solely in the United States. This may magnify volatility due to changes in foreign exchange rates, the political and economic uncertainties in foreign countries, and the potential lack of liquidity, government supervision and regulation.

Common stocks do not assure dividend payments. Dividends are paid only when declared by an issuer's board of directors and the amount of any dividend may vary over time. There can be no guarantee or assurance that companies will declare dividends in the future or that if declared, they will remain at current levels or increase over time.

1 Including sales charges. As of deposit date.

2 Represents the value of 100 units on the deposit date. The value of the minimum investment amount of 100 units may be greater or less than \$1,000.00 following the deposit date.

3 Assuming a public offering price of \$10 per unit. There is no initial sales charge if the public offering price per unit is \$10 or less. If the public offering price per unit exceeds \$10, an initial sales charge is paid at the time of purchase. The per unit amount of the initial sales charge is 2.75% of the dollar amount that the public offering price per unit exceeds \$10.

Before investing, investors should carefully read the prospectus and consider the investment objectives, risks, charges and expenses. For this and more complete information about the trust, investors should ask their financial professional(s) for a prospectus or download one at invesco.com/uit.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

Invesco unit investment trusts are distributed by the Sponsor, Invesco Capital Markets, Inc. and broker dealers including Invesco Distributors, Inc. Both firms are indirect, wholly owned subsidiaries of Invesco Ltd.

Diversified Healthcare Portfolio 2024-1

invesco.com/uit